Pigment dispersion syndrome and pigmentary glaucoma: a review and update

INTRODUCTION

Pigment dispersion syndrome (PDS) is a condition where anomalous iridozonular contact leads to pigment dispersion throughout the anterior segment and the released pigment is abnormally deposited on various ocular structures.

CLINICAL PRESENTATION

The clinical presentation of PDS is defined by the presence of pigmented cells on the corneal endothelium, an increase of pigmentation of the trabecular meshwork, and mid-periphery transillumination defects of the iris. This syndrome, more common in myopes, is usually bilateral and can be associated with ocular hypertension or glaucoma. Secondary open-angle pigmentary glaucoma (PG) can develop due to reduction of the outflow of aqueous humour and consequent increase in intraocular pressure leading to glaucomatous optic neuropathy. Diagnosis of PG is commonly between 40 and 50 years of age, occurring more frequently in men. The advent of ultrasound biomicroscopy and anterior segment optical coherence tomography has contributed to enhancing our knowledge on the condition. Typical alterations of the anterior segment are the posterior insertion of the iris and iris concavity. Treatment of PG should be initiated early to hinder disease progression, glaucomatous damage, and vision loss. Management is based on medical therapy, laser iridotomy, selective laser trabeculoplasty, and filtration procedures.

CONCLUSIONS

The differential diagnosis of PDS with other disorders can be challenging and awareness of the condition together with meticulous ophthalmologic examination allows early diagnosis followed by appropriate management strategies. The present review is a comprehensive report on the clinical characteristics, pathogenesis, current management, and status quo of PDS and PG.

Interaction between injured corneal epithelial cells and stromal cells

PURPOSE

To review the effects of injured corneal epithelial cells on myofibroblastic cell formation in corneal stroma after excimer laser surgery.

METHODS

Denudation of epithelium alone, photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK), and LASIK with denudation of epithelium were performed in rabbit eyes. Postoperative anterior stromal haze was assessed using a standard scale. Immunohistochemical methods were used to detect alpha-smooth muscle actin (alpha-SMA), a marker of myofibroblastic cells, and type III collagen in subepithelial corneal tissue. Rabbit corneal fibroblasts were cultured on collagen gels with or without cocultured corneal epithelial cells, or with partially scraped epithelial cells, on a companion plate separated by a permeable membrane. Gel thickness was measured daily to evaluate fibroblast-induced gel contraction. The total number of fibroblasts per gel was determined. Myofibroblasts were counted using immunocytochemical identification with alpha-SMA. Transforming growth factor (TGF)-beta was assayed in media on days 3 and 6; these procedures were also carried out in the presence of anti-TGF-beta antibody.

RESULTS

Three weeks after surgery, the presence of alpha-SMA-positive long-extended and spindle-shaped stromal cells as well as synthesis of type III collagen were observed in the subepithelial stromal layer, corresponding to corneal haze, in eyes that underwent PRK and LASIK with denudation of epithelium, but not in those that underwent denudation of epithelium alone or LASIK. Gel contraction, number of alpha-SMA-positive cells, and total cell number were significantly greater on gels with injured epithelial cells than on those without epithelial cells or with uninjured epithelial cells, as was TGF-beta concentration in media. Anti-TGF-beta antibody eliminated these differences.

CONCLUSIONS

The intact corneal epithelium might play an important role in curbing differentiation of myofibroblasts in corneal wound healing. Injured epithelial cells stimulate fibroblast myodifferentiation through one or more soluble factors, including TGF-beta.

Prospective Study of Photorefractive Keratectomy for Myopia Using the VISX StarS2 Excimer Laser System

PURPOSE

To evaluate the safety, efficacy, and predictability of excimer laser photorefractive keratectomy (PRK) for compound myopic astigmatism using the VISX StarS2 excimer laser system with international version 3.1 software.

METHODS

We report a prospective consecutive study of myopic excimer laser PRK, performed in a multi-surgeon environment with 200 eyes of 117 patients, to correct naturally occurring compound myopic astigmatism of between -0.50 to -5.90 D manifest refractive sphere and up to -3.50 D manifest refractive astigmatism. Patients were assessed prior to surgery and at 1, 3, 6, and 12 months after treatment.

RESULTS

One hundred and ninety-eight of 200 treatments (99%) were reviewed 1 year after surgery; 193 of 198 eyes (97%) achieved 20/40 or better uncorrected visual acuity and 163 of 198 eyes (82%) achieved 20/20 or better. One eye lost two lines of Snellen visual acuity assessed at 12 months but recovered acuity when assessed at 18 months. Mean spherical equivalent corneal plane power was reduced from -3.50 to +0.90 D 1 month after treatment and 0 D at 12 months (SD 0.67 D). Three eyes of three patients underwent further treatment, two with LASIK and one with PRK for residual refractive error. Refractive astigmatism of >1.00 D was reduced from a mean -1.70 to -0.70 D at 1 year after treatment. Vector magnitude was 79% of that intended and mean vector axis error (absolute) was 8.5 degrees. No eye had a severe haze response. Pelli-Robson contrast acuity was significantly reduced after treatment from a mean 1.72 D preoperatively to 1.63 D at 12 months (P<.01).

CONCLUSIONS

PRK for myopia using the VISX StarS2 excimer laser system was effective in the treatment of low myopic astigmatism, although there was a significant reduction in Pelli-Robson contrast sensitivity.

Laser in situ keratomileusis for the correction of myopia and myopic astigmatism

PURPOSE

To evaluate the efficacy, safety, predictability, and surgically induced astigmatism (SIA) of laser in situ keratomileusis (LASIK) for the correction of myopia and myopic astigmatism.

SETTING

Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.

METHODS

This retrospective study comprised 69 eyes that had LASIK to correct myopia and 74 eyes that had LASIK to correct myopic astigmatism. The excimer laser keratectomy was performed using a Summit Apex Plus machine. Refraction, visual acuity, and computerized corneal videokeratography data from the preoperative and postoperative examinations were collected. The astigmatic change was calculated by the Alpins vector analysis method.

RESULTS

The preoperative spherical equivalent at the glasses plane in the myopia and myopic astigmatism groups was -8.08 diopters (D) and -9.73 D, respectively. At 6 months, the spherical equivalent and residual corneal astigmatism were -0.25 D and 0.85 D, respectively, in the myopia group and -0.71 D and 0.82 D, respectively, in the myopic astigmatism group. In the myopia group, 88% of eyes were within +/-1.0 D of the intended myopia correction and in the myopic astigmatism group, 85% were within +/-1.0 D of the targeted spherical equivalent and 90% were within +/-1.0 D of the intended astigmatism correction. The uncorrected visual acuity was 20/40 or better in 94.1% of eyes in the myopia group and 92.5% of eyes in the myopic astigmatism group. The SIA magnitude was 0.66 D with the axis randomly distributed in the myopia group. The mean astigmatism correction index was 0.97, the mean magnitude of error was 0.13 D +/- 0.62 (SD), and the mean angle of error was -3.70 +/- 13.73 degrees in the myopic astigmatism group.

CONCLUSION

Laser in situ keratomileusis had similar predictability, safety, and efficacy in the treatment of myopia and myopic astigmatism. The astigmatism correction was effective, but the results suggest that subjective astigmatism of less than 1.0 D need not be treated with the Summit Apex Plus laser.

Photorefractive Keratectomy for Astigmatism With the Meditec MEL 60 Laser

PURPOSE

To evaluate the results of photorefractive keratectomy (PRK) in eyes treated with astigmatic refractive errors.

METHODS

Nine hundred forty eyes were treated with the Aesculap Meditec MEL 60 ArF excimer laser. Treatment groups were: Group 1 (n=746) eyes with compound myopic astigmatism, Group 2 (n=104) eyes with compound hyperopic astigmatism, Group 3 (n=75) eyes treated for mixed astigmatism, and Group 4 (n=15) eyes with simple myopic astigmatism (negative cylinder).

RESULTS

In Group 1, the preoperative spherical equivalent refraction of -6.10 D with an average of -1.50 D cylinder decreased to -0.95 D with -0.13 D cylinder; uncorrected visual acuity (UCVA) of 20/40 or better was achieved in 86% (642/746 eyes); 20/20 or better in 58% (433/746 eyes); 0.8% (6/746 eyes) lost two lines of spectacle-corrected visual acuity (SCVA); 74% (552/746 eyes) were within +/-0.50 D and 93% (694/746 eyes) were within +/-1.00 D of target refraction. In Group 2, preoperative mean +4.57 D spherical equivalent refraction with an average of +1.57 D cylinder decreased to +1.13 D with +0.38 D cylinder; UCVA of 20/40 or better was achieved in 84% (87/104 eyes); 20/20 or better in 46% (48/104 eyes); 14,4% (15/104 eyes) lost two or more lines of SCVA; 52% (54/104 eyes) were within +/-0.50 D and 82% (85/104 eyes) were within +/-1.00 D of target refraction. In Group 3, mean preoperative -4.20 D cylinder and +3.00 D spherical equivalent refraction decreased to -0.50 D cylinder and -0.50 D spherical equivalent refraction; UCVA of 20/40 or better was achieved in 83% (62/75 eyes); 20/20 or better in 32% (24/75 eyes); 13.3% (10/75 eyes) lost two or more lines of SCVA. In Group 4, mean preoperative -3.98 D cylinder decreased to -0.62 D cylinder; UCVA of 20/40 or better was achieved in 60% (9/15 eyes); none of the eyes achieved 20/20 or better; SCVA remained stable in 6.6% (1/15 eyes) and decreased two or more lines in 20.0% (3/15 eyes); 20% (3/15 eyes) were within +/-0.50 D and 53.3% (8/15 eyes) were within +/-1.00 D of target refraction.

CONCLUSION

PRK with the Meditec MEL 60 laser produced the best results in eyes with compound myopic astigmatism (Group 1). In all other groups, results were less predictable.

Advances in refractive surgery: 1975 to the present

PURPOSE

To review the major advances in the field of refractive surgery occurring over the past 25 years.

METHODS

Literature review.

RESULTS

The major developments in refractive surgery over the past 25 years are reviewed.

CONCLUSIONS

The past 25 years have witnessed great changes in refractive surgery. As a result of advancements in technology, instrumentation, and technique, we have seen improvements in the treatment of all types of ametropias. In this article, we review some of the successes and failures of the past quarter-century.